Rarebase
Clayton Mellina has a diverse work experience, starting with their current role as the VP of Software Engineering at Rarebase from 2022. Prior to this, they held the position of Director of Software Engineering at Rarebase from 2022 to 2023.
Before joining Rarebase, Clayton worked at Google from 2017 to 2022. Their role as a Staff Software Engineer and Computer Vision Lead involved leading applied computer vision research and development efforts for Google Cloud products, including the Vertex AI Vision retail stock monitoring API. Clayton also led the research and launch of the Google Visual Inspection AI, an AutoML product for manufacturers.
From 2013 to 2017, Clayton worked at Yahoo as a Software Engineer, where they were a founding member of the computer vision team at Flickr. Clayton implemented a vector search system and launched visual similarity search for Flickr.
Prior to Yahoo, Clayton was a Software Engineer at LookFlow, a startup that developed a new way to explore image collections. LookFlow was eventually acquired by Yahoo.
Clayton's early work experience includes being a Symbolic Systems Program Student Advising Fellow at Stanford University from 2010 to 2012, where they advised undergraduate Symbolic Systems majors and received the Barwise Award for their contributions to the program.
Clayton Mellina holds a Bachelor of Science degree in Symbolic Systems - Cognitive Science from Stanford University, which they obtained from 2007 to 2011. Clayton then pursued a Master of Science degree in Computer Science at Stanford University from 2010 to 2012, with a dual focus in Human-Computer Interaction and Artificial Intelligence. Clayton also obtained additional certifications in various subjects from Coursera in 2013, including Computational Molecular Evolution, Epigenetic Control of Gene Expression, Programmed cell death, and Introduction to Systems Biology.
Rarebase
Rarebase is enabling a better life for the 400 million people living with rare disease. With a product engine designed to discover treatments for hundreds of monogenic diseases simultaneously, Rarebase is focused on the largest untapped drug discovery opportunity in human health: rare diseases. Rarebase has already uncovered potential treatments for hundreds of rare diseases. The company has also built a “drug-gene atlas” to enable AI-driven drug discovery.